Over the past year, precision medicine in the Asia-Pacific region has witnessed significant advancements. Countries like Singapore, China, and South Korea have made progress in genomic sequencing, biomarker development, and the creation of large-scale biobanks, and there is a growing focus on developing companion diagnostics to identify patients most likely to benefit from specific therapies.

The World Companion Diagnostics & Liquid Biopsy Summit APAC arrived in Singapore this November 13-14 to "provide an exceptional platform for knowledge sharing, collaboration, and the exchange of innovative ideas. This collaborative environment will foster intellectual growth, promote thought leadership, and drive positive change in the field". And that's a direct quote from one of the 2024 speakers!

You could have joined 100+ of your colleagues working within Precision Medicine, Companion Diagnostics, Biomarker Development, Regulation and more from across the Asia-Pacific region to accelerate precision therapeutics to patients in oncology and beyond.